Riskpilot← Back to searchSign inGet full accessMITO BIOTECH AS
ASActiveOrg 916496664Haukelandsbakken 31, 5009 BergenMarine fishing · NACE 0311Est. 20160 employees
Revenue 2024
NOK 475
-99% vs 2023
EBITDA margin
-10678.9%
+70% vs 2023
Equity ratio
98.2%
Financial strength
Net profit 2024
NOK -143K
+53% vs 2023
| Revenue | NOK 475 | -99% |
| EBITDA | NOK -51K | +70% |
| Net profit | NOK -143K | +53% |
| Total assets | NOK 825K | +91% |
| Equity | NOK 810K | +101% |
| Employees | 0 | — |
Legal name
MITO BIOTECH AS
Org number
916496664
Legal form
Aksjeselskap
NACE code
0311 · Marine fishing
Founded
13. januar 2016
Share capital
NOK 305 200
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styreleiar åleine.
Company purpose
Å høste og produsere tare og tilhørende produkter.
Address
Haukelandsbakken 31, 5009 Bergen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 400 | 282 | 330 | 371 | 219 | 68 | 4 | 50 | 0 |
| Staff expenses | −0 | −399 | −264 | −5 | 24 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | −720 | −1 172 | 1 210 | −1 095 | 126 | −6 620 | −283 | −170 | −51 |
| Depreciation & amort. | −0 | −0 | −0 | −6 | −74 | −91 | −141 | −207 | −155 | −102 |
| EBIT | 0 | −720 | −1 172 | 1 204 | −1 169 | 36 | −6 761 | −489 | −325 | −153 |
| Net financials | 0 | −0 | −0 | −1 | −5 | 248 | −446 | −143 | 22 | 9 |
| Profit before tax | 0 | −720 | −1 172 | 1 203 | −1 174 | 284 | −7 207 | −633 | −303 | −143 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −720 | −1 172 | 1 203 | −1 174 | 284 | −7 207 | −633 | −303 | −143 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 45 | 245 | −0 | 948 | 9 757 | 9 941 | 3 627 | 1 307 | 431 | 825 |
| Equity | 35 | −685 | −1 856 | −654 | 8 863 | 9 147 | 1 940 | 1 307 | 403 | 810 |
| Long-term debt | 0 | 0 | 0 | 1 449 | 0 | 727 | 1 138 | 0 | 0 | 0 |
| Short-term debt | 10 | 930 | 1 856 | 152 | 894 | 68 | 549 | 0 | 28 | 15 |
| Total debt | 10 | 930 | 1 856 | 1 602 | 894 | 794 | 1 687 | 0 | 28 | 15 |
EBITDA margin
-10678.9%
This company
15.8%
Market median
-67688% vs market
20152024
Equity ratio
98.2%
This company
38.2%
Market median
+157% vs market
20152024
Return on equity
-17.7%
This company
18.4%
Market median
-196% vs market
20152024
Net profit margin
-30183.8%
This company
8.1%
Market median
-372740% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-10-28 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TA Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Daimyo Invest As | Company | 42.9% | 42.9% | 2024 |
| Individual | 22.2% | 22.2% | 2024 | |
Bergen Shipping As | Company | 22.2% | 22.2% | 2023 |
| Individual | 17.6% | 17.6% | 2024 | |
| Individual | 17.3% | 17.3% | 2024 | |
| Individual | 14.3% | 14.3% | 2022 | |
Drønen Havfiske As | Company | 14.3% | 14.3% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MITO BIOTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Aquinas Aloysius | Chief Executive Officer | 0 companies |
| Michael Lodahl | Board of Directors | 0 companies |
| Torstein Christiansen | Chairman | 0 companies |
| Rolf Kristian Berge | Chairman | 0 companies |
| Hans Cato Haddal | Board of Directors | 0 companies |
| Rune Johan Ulvik | Board of Directors | 0 companies |
| Nils Arve Drønen | Board of Directors | 0 companies |
| Gunnar Buvik | Board of Directors | 0 companies |
| Leiv Kristen Sydnes | Board of Directors | 0 companies |